Pds biotechnology reschedules 2021 fourth quarter and full year financial results and conference call

Florham park, n.j., march 22, 2022 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the company's proprietary versamune® and infectimune™ t-cell activating technologies, today announced that it has changed the date of its previously announced 2021 fourth quarter and full year earnings release call from wednesday, march 23, 2022 to 8:00 am edt on thursday, march 31, 2022 as pds biotech needs additional time to complete its audit and file its annual report on form 10-k for the fiscal year ended december 31, 2021. following the release, management will host a conference call to review the financial results and provide a business update.
PDSB Ratings Summary
PDSB Quant Ranking